A novel strategy to increase the proliferative potential of adult human β-cells while maintaining their differentiated phenotype by Aly, Haytham et al.




A novel strategy to increase the proliferative
potential of adult human β-cells while maintaining
their differentiated phenotype
Haytham Aly
Washington University School of Medicine in St. Louis
Nidhi Rohatgi
Washington University School of Medicine in St. Louis
Connie A. Marshall
Washington University School of Medicine in St. Louis
Tiffani C. Grossenheider
Washington University School of Medicine in St. Louis
Hiroyuki Miyoshi
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Aly, Haytham; Rohatgi, Nidhi; Marshall, Connie A.; Grossenheider, Tiffani C.; Miyoshi, Hiroyuki; Stappenbeck, Thaddeus S.;
Matkovich, Scot J.; and McDaniel, Michael L., ,"A novel strategy to increase the proliferative potential of adult human β-cells while
maintaining their differentiated phenotype." PLoS One.8,6. e66131. (2013).
http://digitalcommons.wustl.edu/open_access_pubs/1700
Authors
Haytham Aly, Nidhi Rohatgi, Connie A. Marshall, Tiffani C. Grossenheider, Hiroyuki Miyoshi, Thaddeus S.
Stappenbeck, Scot J. Matkovich, and Michael L. McDaniel
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/1700
A Novel Strategy to Increase the Proliferative Potential
of Adult Human b-Cells While Maintaining Their
Differentiated Phenotype
Haytham Aly1, Nidhi Rohatgi1, Connie A. Marshall1, Tiffani C. Grossenheider2, Hiroyuki Miyoshi1,
Thaddeus S. Stappenbeck1, Scot J. Matkovich2, Michael L. McDaniel1*
1Department of Pathology and Immunology Washington University in St. Louis, St. Louis, Missouri, United States of America, 2Center for Pharmacogenomics,
Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, United States of America
Abstract
Our previous studies demonstrated that Wnt/GSK-3/b-catenin and mTOR signaling are necessary to stimulate proliferative
processes in adult human b-cells. Direct inhibition of GSK-3, that engages Wnt signaling downstream of the Wnt receptor,
increases b-catenin nuclear translocation and b-cell proliferation but results in lower insulin content. Our current goal was to
engage canonical and non-canonical Wnt signaling at the receptor level to significantly increase human b-cell proliferation
while maintaining a b-cell phenotype in intact islets. We adopted a system that utilized conditioned medium from L cells
that expressed Wnt3a, R-spondin-3 and Noggin (L-WRN conditioned medium). In addition we used a ROCK inhibitor (Y-
27632) and SB-431542 (that results in RhoA inhibition) in these cultures. Treatment of intact human islets with L-WRN
conditioned medium plus inhibitors significantly increased DNA synthesis ,6 fold in a rapamycin-sensitive manner.
Moreover, this treatment strikingly increased human b-cell proliferation ,20 fold above glucose alone. Only the
combination of L-WRN conditioned medium with RhoA/ROCK inhibitors resulted in substantial proliferation. Transcriptome-
wide gene expression profiling demonstrated that L-WRN medium provoked robust changes in several signaling families,
including enhanced b-catenin-mediated and b-cell-specific gene expression. This treatment also increased expression of
Nr4a2 and Irs2 and resulted in phosphorylation of Akt. Importantly, glucose-stimulated insulin secretion and content were
not downregulated by L-WRN medium treatment. Our data demonstrate that engaging Wnt signaling at the receptor level
by this method leads to necessary crosstalk between multiple signaling pathways including activation of Akt, mTOR, Wnt/b-
catenin, PKA/CREB, and inhibition of RhoA/ROCK that substantially increase human b-cell proliferation while maintaining the
b-cell phenotype.
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Introduction
Inadequate b-cell mass is a defect common to both types 1 & 2
diabetes (T1DM, T2DM). Although adult human b-cells have
very low proliferation rates in vivo, significant levels of proliferation
occur, for example during pregnancy and conditions of insulin
resistance, indicating the existence of regulatory mechanisms.
Multiple investigators have highlighted the importance of self-
duplication in vivo as the major source of postnatal b-cell expansion
although contributions from stem cells are not excluded [1–3].
However, in vitro studies by Rutti et al. found that proliferation of
dispersed human b-cells is a very rare event that was not
significantly enhanced using a variety of trophic factors and
matrices [4]. In addition, Neilson et al. observed that intact
isolated human islets remained functional for months, but did not
proliferate under the culture conditions used [5]. Based on this in
vitro proliferation barrier, there is a compelling need to identify the
regulatory mechanisms and strategies that will unmask the
proliferative capacity of pre-existing differentiated adult human
b-cells in intact islets, and may lead to the identification of new
drug targets [6].
Several studies have focused on developing strategies to expand
or restore b-cell mass by exploring pathways that drive b-cell
proliferation while maintaining b-cell function [7–14]. Using in
vitro and in vivo models, delivery of transcription factors that
facilitate cell cycle entry, such as hepatocyte nuclear factor-4a
[14], or regulate the cell cycle including c-Myc [13], cyclin D1 [7],
cyclin-dependent kinase 2 (cdk2), cyclin E [12], and cdk6 [8,11],
have been shown to continuously drive the replication of adult
human b-cells.
Our previous in vitro studies demonstrated that engaging the
Wnt/b-catenin pathway by direct GSK-3 inhibition with phar-
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macologic agents in combination with nutrient activation of
mTOR, enhanced DNA synthesis, cell cycle progression and
proliferation of adult human b-cells in a rapamycin-sensitive
manner [15,16]. Our studies also determined that human islets
exhibited insulin signaling pathway resistance, as indicated by a
lack of Akt phosphorylation, in comparison to rodent islets. Insulin
signaling pathway resistance in human islets is due in part to
mTOR/S6K1-mediated feedback inhibition of the insulin-signal-
ing pathway that results in degradation of IRS1/2 [15,17] and
prevents growth factors from activating Akt and subsequent
inhibition of GSK-3. Although treatment of human islets with
inhibitors of GSK-3 circumvented insulin resistance by engaging
the canonical Wnt signaling pathway, Akt signaling was not
restored [18]. Surprisingly, nearly all of the isolated human islets
that we receive display insulin signaling pathway resistance,
although none of the islet donors were diagnosed with type 2
diabetes. The reasons for the insulin signaling pathway resistance
are unclear but may be due to multiple factors including islet
isolation procedures, ischemia/reperfusion injury, shipping, hyp-
oxia, oxidative stress and inflammation [19].
Our present goal is to identify the regulatory mechanisms
necessary to achieve significant proliferation of pre-existing
differentiated adult human b-cells using intact cadaveric islets.
This strategy is achieved by physiologically engaging Wnt
signaling at the receptor level that activates both canonical and
non-canonical Wnt signaling. At the cell surface, Wnt ligands bind
to a G protein-coupled Frizzled (Fzd) receptor and lipoprotein
receptor-like proteins, LRP5/6 co-receptor. This results in
activation of diverse signaling events including b-catenin-depen-
dent transcription (canonical pathway), and several distinct b-
catenin-independent pathways (non-canonical pathways) [20].
In canonical Wnt signaling, the absence of Wnt ligands binding
to surface receptors results in active GSK-3 that phosphorylates b-
catenin, and targets its proteasomal degradation [21]. Upon
activation of Wnt signaling, in the presence of Wnt ligands, GSK-3
is inactivated leading to cytoplasmic accumulation of active b-
catenin that translocates to the nucleus [22] and associates with
other transcription factors including the T-cell factor/lymphocyte
enhancer factor (TCF/LEF). Overall, this cascade results in the
transcription of Wnt-target genes necessary for proliferation [23].
In the non-canonical Wnt pathways, the binding of Wnt
proteins to Fzd and Lrp5/6 receptors leads to the activation of the
Rho and Rac GTPases, which are important regulators of cell
adhesion, transcription regulation and cell cycle progression [15].
Rho GTPase is a member of the Ras superfamily of proteins that
regulates cytoskeletal dynamics [24] and plays critical roles in the
regulation of gene expression and cell proliferation [25–27]. Also
associated with the Rho GTPase pathway are ROCK proteins
that are involved in cytoskeletal processes including migration,
apoptosis, cytokinesis, proliferation and differentiation [28].
In addition to the Wnt glycoproteins, the roof plate-specific
spondin (R-spondin) proteins bind to the LRP5/6 receptor and
activate Wnt signaling in association with b-catenin activation
[29]. The R-spondin protein family (RSpo) consists of 4 members
(RSpo 1–4) that share ,60% sequence similarity and comparable
domain organization [30]. All four RSpo proteins associate with
Wnt/b-catenin signaling family members and induce proliferation
of crypt epithelial cells that lead to enlargement of the mouse
gastrointestinal tract [30,31]. A recent study by Kazanskaya et al.
demonstrated that R-spondin-3 is required for Wnt/b-catenin-
mediated activation of vascular endothelial growth factor (VEGF)
signaling [32]. Furthermore, Wong et al. demonstrated that mouse
islets express R-spondin-1 protein that leads to activation of
canonical Wnt signaling and increased b-cell proliferation and
insulin secretion [33].
In addition to Wnt and mTOR signaling, the cyclic AMP-
dependent protein kinase A (PKA) pathway also plays an
important role in the regulation of gene expression, function,
and proliferation of b-cells [34]. PKA mediates inhibition of GSK-
3 by two independent mechanisms: a direct phosphorylation of
GSK-3 [34] and by activation of Akt that inhibits GSK-3 [35–38].
In addition, stimulation of PKA by cAMP leads to the
phosphorylation of cyclic AMP response element binding protein
(CREB) at Ser133 that enhances the transcription of proliferation-
related genes [39]. GSK-3b regulates CREB activity by phos-
phorylating CREB at Ser129 [40] and increases its transcriptional
activity [33,41].
Here we utilized a system to deliver Wnt and R-spondin ligands
to cultured cells. This system involves the use of conditioned
medium from L-cells that constitutively produce Wnt3a, R-
spondin-3 and Noggin. This system has been successfully used to
grow mouse colonic epithelial cells that are enriched for stem cells.
Our goal was to test if this system could be adapted to human islet
cells in culture. We found that this unique conditioned medium
has allowed us to significantly increase proliferation while
maintaining differentiation of adult human b-cells in intact islets.
This novel strategy engages both canonical and non-canonical
Wnt signaling, and in combination with RhoA/ROCK inhibition
removes insulin signaling pathway resistance and allows necessary
crosstalk between Wnt/GSK-3/b-catenin, Akt/mTOR, and




Lithium chloride (LiCl) and ROCK inhibitor (Y-27632) were
from Sigma. Connaught Medical Research Laboratories (CMRL)
1066 media, penicillin, streptomycin, Hank’s balanced salt
solution (HBSS) were from Invitrogen. PKA inhibitor, [N-[2-(p-
Bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide. 2HCl]
(H-89) and rapamycin were from Enzo Life Sciences International,
Inc. TGF-b type 1 receptor inhibitor (SB-431542) was from
Calbiochem. Akt inhibitor XII was from Millipore. Defined fetal
bovine serum (FBS) was from Hyclone. 3H-thymidine-aqueous, 2
Ci/mmol, 1 mCi/ml was from Perkin-Elmer and American
Radiolabeled Chemical, Inc. All primary antibodies used were
from Cell Signaling. The peroxidase-conjugated secondary anti-
bodies were obtained from Jackson ImmunoResearch laboratories.
All other chemicals were from commercially available sources.
Ethics Statement
Isolated cadaver-derived human islets were obtained from the
Integrated Islet Distribution Program (IIDP) sponsored by the
NIDDK and the JDRFI and the JDRFI Sponsored Islets for
Research Program at Washington University (JDRF-31-2008-
382). The IIDP uses only cadaver donors that have consented to
research. The Washington University Medical Center (WUMC)
Human Studies Committee (HSC) IRB approved all studies
involving the use of isolated cadaver-derived human islets
(Approval number: 93-0068). The IRB exempted the study from
HIPAA compliance based on regulatory definition of human
subject. Review date: 7/8/2004; review committee: 08 MRCR.
Human Islets
Upon arrival, the islets were collected by centrifugation, cleaned
and hand-selected in cCMRL under a stereomicroscope and
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treated immediately or after overnight culture at 37uC. Human
islet donor data: 26 donors; 9 males, 12 females and 5 not
documented; age, mean 41.8 yrs (range 17–65); BMI, mean 28.7
(range 22.3–38.4); purity, mean 85.8% (range 50–95%); and
viability, mean 92.9% (range 85–95%). None of the donors were
diagnosed with diabetes.
Conditioned Media
Wnt3a, R-spondin-3 and Noggin (L-WRN) conditioned medi-
um based on CMRL (Invitrogen) supplemented with 10% FBS
was constructed as previously described [42]. Briefly, L-WRN
conditioned medium was prepared from mouse L cells stably
expressing Wnt3a, cells transfected with R-spondin-3 and Noggin
expression vector and doubly-selected in media containing
hygromycin and G418 (Sigma). L-WRN+ conditioned medium
was prepared by adding 10 mM Y-27632 and 10 mM SB-431542
inhibitors to L-WRN conditioned medium. Conditioned medium
collected from wild type L-cells was used as a control.
3H-Thymidine Incorporation
Islets (100) were cultured in Petri dishes (35610 mm) for 4 days
in 1 ml CMRL (5 or 8 mM glucose, 10% FBS, 2 mM L-
glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin)
containing treatment conditions, as indicated in the figure legends,
at 37uC, under 95% air/5% CO2.
3H-thymidine was added to
each dish at a final concentration of 10 mCi/ml during the last
24 h. The incorporation of 3H-thymidine into DNA was
determined by trichloroacetic acid precipitation and scintillation
counting.
Quantitative Real Time RT-PCR
Islets (100) were cultured for various times in 1 ml of CMRL (5,
8 or 20 mM glucose, 10% FBS, 2 mM L-glutamine, 100 units/ml
penicillin, 100 mg/ml streptomycin) under different treatment
conditions, as indicated in the figure legends, at 37uC, under 95%
air/5% CO2. The total RNA was extracted using Qiagen
RNAeasy kit (Qiagen) according to the manufacturer’s instruc-
tions. First-strand cDNA was synthesized from 0.5–1 mg of total
RNA using a High Capacity cDNA Reverse Transcription kit
(Applied Biosystems). The expressions of the analyzed genes were
investigated using pre-designed TaqMan primers/probes (Applied
Biosystems), and all probes were 6-carboxyfluorescein (FAMTM)
fluorescently labeled with a 39 non-fluorescent quencher, MGB.
100 nanograms of reversed-transcribed total RNA and Taqman
Gene Expression MasterMix in a total volume of 20 mL PCR
reaction was performed using StepOnePlus Real-Time PCR
system (Applied Biosystems). Amplifications for each gene were
carried out in triplicate, and mean values were normalized to the
mean value of the endogenous control, b-actin. The relative fold
changes of the analyzed genes were calculated using the
comparative threshold cycle method (22DDCt) [43].
RNA-Sequencing
Two islet preparations (from different donors) were subjected to
RNA-sequencing; within each preparation, subsets of islets were
treated with 5 or 8 mM glucose, 8 mM glucose+5 mM LiCl or
8 mM glucose together with L-WRN+ for 48 h immediately after
initial receipt and hand-selection. Polyadenylated mRNA was
obtained from 1 mg of human islet total RNA using oligo(dT)-
coupled Dynabeads (Invitrogen), and mRNA-sequencing library
preparation was performed essentially as described [44,45], using
Illumina HiSeq 2000 sequencers and 39 library indexing rather
than 59 bar-coding. Raw sequence files have been deposited in the
NCBI sequence read archive (SRA) with the accession ID
SRA072806 (http://www.ncbi.nlm.nih.gov/sra/
?term=SRA072806). The ‘transcriptome-only’ alignment func-
tion of TopHat 1.4.0 [46] was used together with the Ensembl
GRCh37 human genome sequence and associated transcriptome
map (gtf) provided through the Illumina iGenomes project
(download available at http://tophat.cbcb.umd.edu/igenomes.
html) to align 50 nt single-end sequencing reads. The aligned
read count for each sequencing library (i.e. treated islet sample)
was 8.560.7 million (mean 6 standard error of the mean).
Filtering of RNA-Sequencing Data, Differential Gene
Expression, and Categorization
The DESeq package [47] was used to normalize read depth
across different sequencing libraries and to calculate fold-changes
between treated islet samples. Expression of each mRNA is
reported as the normalized number of reads mapped to each
mRNA. mRNAs with fewer than 8 reads mapping in any sample
(i.e. less than 1 millionth of the total number of reads) were
removed from further consideration. Those mRNAs regulated in
response to L-WRN+ treatment were defined as those with at least
a 1.5 fold-change (in either direction) between L-WRN+ and
8 mM glucose-treated islets from the same donor, and for which
the same degree and direction of fold-change was observed in islet
preparations from both donors. Partek Genomics Suite 6.6
(Partek, St. Louis, MO) was used to perform unsupervised
hierarchical clustering with Euclidean dissimilarity and average
linkage, and to derive heatmaps. The MetaCore online suite of
gene network analytic tools (Thomson Reuters) was used to
interrogate regulated mRNAs for membership in Gene Ontology
categories and custom MetaCore network groups. Pathway
diagrams in MetaCore were prepared with the restriction that
genes displayed had to be present in human islets.
Insulin Secretion and Content
Islets were cultured for 5 days in CMRL-1066 medium
containing 10% FBS, 8 mM glucose or in L-WRN610 mM
RhoA/ROCK inhibitors as indicated in the figure legend. At the
end of 5 days, islets were incubated for 2 h or 24 h in CMRL
containing 5 mM glucose and then four aliquots of 10 islets were
counted for each treatment group. Islets were preincubated for
30 min in CMRL (5 mM glucose), and media was replaced with
CMRL with 5, 16.5 mM glucose, or 16.5 mM glucose+10 mM
forskolin for 1 h. Insulin secreted in the culture supernatant was
assayed by Immulite solid-phase competitive chemiluminescent
enzyme immunoassay kit from Siemens Healthcare Diagnostics
Inc. Islet insulin content was measured in separate batches of 20
islets after ethanol/acid (77% ethanol, 1% hydrochloric acid)
extraction. Insulin content from three aliquots of 20 islets was also
measured at the start of the incubation period (Time 0). Islet
proteins were extracted using RLT extraction buffer (Invitrogen)
and quantified with BioRad Bradford reagent. The insulin values
were normalized for the total protein content extracted from the
same islets.
Western Blot Analysis
Groups of 150–200 islets were incubated in CMRL medium
and treated as indicated in the figure legends. Islet proteins were
prepared using the Nuclear Extract Kit (Active Motif) according to
the instructions of the manufacturer. Protein concentrations were
measured using the BioRad Bradford reagent. Fifteen micrograms
of each sample were loaded in each lane of a 4–12% Bis-Tris
polyacrylamide gel (Invitrogen). Proteins were transferred to a
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nitrocellulose membrane, and the membrane blocked with 5%
nonfat milk for 1 h, incubated with the antibody (1:1000) against
the desired protein overnight at 4uC, washed, incubated with the
appropriate secondary antibody (1:5000) for 1 h at room
temperature, washed again, and developed using ECL (Amer-
sham) or Immun-Star WesternC (BioRad).
Immunohistochemistry
Human islets (65) were treated for 5 days, washed with cold PBS
and then dissociated into single-cell suspension by incubation in
1 mL Accutase (Innovative Cell Technologies) at room temper-
ature for 15–30 min and dispersed by gentle pipetting. Single-cell
suspensions were cytospun onto coated slides (3000–4000 cells/
slide). Cells were fixed in 4% paraformaldehyde (Electron
Microscopy Sciences) for 30 min, permeabilized using 1% triton
X-100 for 20 min, and blocked with 3% BSA for 1 h at room
temperature. Indirect immunofluorescence was performed using
primary antibodies, rabbit anti-insulin (1:100; Cell Signaling),
mouse anti-Ki-67 (1:100; Dako), and secondary antibodies, Alexa
488 goat anti-rabbit (1:1000) and Alexa 555 goat anti-mouse
(1:1000) (Molecular Probes). Nuclei were counterstained with 49,
Figure 1. L-WRN conditioned medium activates the Wnt/b-catenin signaling pathway. (A) 100 islets were cultured for 4 days in CMRL-1066
medium containing 10% FBS and 5, 8 or 20 mM glucose or in 50% Wnt3a, R-spondin-3 and Noggin conditioned medium (L-WRN)+Y-27632 and SB-
431542 inhibitors. 3H-thymidine was added 24 h before the end of the 4-day period. (B) & (C): islets (150) were treated for 24 h and 72 h, respectively,
in CMRL-1066 medium containing 10% FBS and 5 mM glucose 6 5 mM LiCl or in 50% L-WRN 6 Y-27632 and SB-431542 inhibitors. Samples were
processed for Western blotting and quantitated by Image LabTM software. pGSK-3b and non-p-b-catenin proteins were normalized to total GSK-3b
and total b-catenin proteins, respectively. Data are the means 6 SE of n = 3. *P,0.05, **P,0.01 and ***P,0.001 denote significant differences
between the treatment condition and the control.
doi:10.1371/journal.pone.0066131.g001
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69- diamindino-2-phenylindole (DAPI; Molecular Probes). All
microscopy was performed using a Nikon TE300 microscope
equipped with CoolSNAP ES2 camera (Photometrics); images
were acquired using the MetaMorph software package (Molecular
Devices) with 161 binning and 128 pixels6128 pixels imaging
field.
Expression of Data and Statistics
All data are expressed as means 6 standard error (SE).
Statistical analyses were performed using unpaired t tests or one-
way ANOVA followed by Newman-Keuls multiple comparison
test. Significant differences are indicated by *P,0.05, **P,0.01,
***P,0.001.
Results
Activation of the Wnt signaling pathway with Wnt3a/R-
spondin-3, Noggin containing conditioned media (L-
WRN) and RhoA/Rock inhibitors (L-WRN+)
As a novel method to stimulate Wnt signaling, in human islet
cells, we utilized 50% conditioned medium from L-cells that
constitutively express Wnt3a, R-spondin-3 and Noggin (L-WRN)
[42]. This experimental system was previously developed to
expand the stem cell population of cultured mouse colon epithelial
cells [42]. To augment cell survival we additionally added ROCK
and RhoA inhibitors [48,49]. We found that the L-WRN+
medium (containing RhoA and ROCK inhibitors) stimulates a
striking level of DNA synthesis in islet cells cultured in 5 mM
glucose. In contrast elevated levels of glucose did not stimulate
DNA synthesis (Figure 1A). Thus the L-WRN medium plus
inhibitors can overcome the well-known resistance of cultured islet
cells to mitotic insulin signaling [16–18,50,51].
Previously, we determined that inhibition of GSK-3 with LiCl,
to engage Wnt signaling, resulted in a significant increase in DNA
synthesis [6]. In Figure 1B, we compared activation of down-
stream targets by LiCl and L-WRN conditioned medium.
Treatment of human islets for 24 h with LiCl resulted in a
significant increase in pGSK-3b (Ser9, arrow). However, L-WRN
and L-WRN+ treatment did not significantly increase pGSK-3b
(Ser9). Active GSK-3b (non-phosphorylated) destabilizes and
degrades b-catenin by phosphorylation of Ser33, Ser37, and
Thr41 [52]. In Figure 1C, treatment of human islets for 24 h with
L-WRN conditioned medium (plus or minus RhoA/ROCK
inhibitors) or LiCl significantly enhanced the accumulation of
non-phosphorylated b-catenin protein (active form) in human
islets (arrow).
These results suggest that, in addition to the effects on Wnt
activation, the conditioned media may also enhance the accumu-
lation of active b-catenin via a Wnt-independent mechanism
[30,53,54].
mTOR dependency of L-WRN+ conditioned media-
stimulated DNA synthesis in human islets
In Figure 2A, treatment of human islets for 4 days with LiCl
resulted in a significant increase (,2.5 fold) in DNA synthesis
compared to 5 mM glucose (lanes 1 vs. 3). Treatment with L-
WRN conditioned medium or RhoA/ROCK inhibitors alone, or
in combination with LiCl did not significantly increase DNA
synthesis above 5 mM glucose. However, treatment with L-
WRN+ significantly enhanced DNA synthesis ,6 fold above that
of 5 mM glucose (lanes 1 vs. 6). Figure 2B shows that treatment of
human islets with rapamycin 25 or 100 nM significantly inhibited
DNA synthesis induced by L-WRN+, indicating that L-WRN+
mediated DNA synthesis is mTOR-dependent.
Figure 2. Activation of Wnt and inhibition of RhoA/ROCK signaling significantly increase DNA synthesis in human islets and is
mTOR-dependent. (A & B) Islets (100) were cultured for 4 days in CMRL-1066 medium containing 10% FBS and 5 mM glucose or in 50% Wnt3a, R-
spondin-3 and Noggin conditioned medium (L-WRN) 6 5 mM LiCl 6 Y-27632 and SB-431542 inhibitors 625 or 100 nM rapamycin as indicated. 3H-
thymidine was added 24 h before the end of the 4-day period. Data are the means 6 SE of n= 3. *P,0.05, **P,0.01 and ***P,0.001 denote
significant differences between the treatment condition and the control.
doi:10.1371/journal.pone.0066131.g002
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L-WRN+ treatment increases b-cell proliferation and
increases expression of b-cell specific genes
The ability of L-WRN+ to enhance the proliferation of human
b-cells in intact islets was next determined. Human islets were
treated with 5 or 8 mM glucose, L-WRN or L-WRN+ for 5 days
followed by dispersion of islets into single cells and stained for Ki-
67 and insulin to quantify b-cell proliferation. Figure 3A
demonstrates that L-WRN in the presence of 5 or 8 mM glucose
did not significantly increase the number of Ki-67+/insulin+ cells
compared with 5 or 8 mM glucose alone. However, culturing with
L-WRN+ significantly increased Ki-67+/insulin+ cells ,20-fold
above glucose alone (lanes 1 vs. 5 or 2 vs. 6). Figure 3B is a
representative immunofluorescence image of dispersed human
islet cells, previously treated for 5 days with L-WRN+ at 5 mM
glucose, showing colocalization of Ki-67+ (red nuclei) and insulin+
(green cytoplasm) b-cell. All nuclei are identified by DAPI staining
(blue). Since similar effects were observed at both 5 and 8 mM
glucose, the dramatic increase in b-cell proliferation in response to
L-WRN+ was not glucose-dependent.
Due to the significant effects of L-WRN+ on increasing DNA
synthesis in human islets and proliferation in human b-cells, we
determined if L-WRN+ treatment affected mRNA expression of
key b-cell specific transcription factors assayed by qRT-PCR.
Incubation of islets for 8 h with L-WRN+ increased gene
expression of Insulin, Pdx1, Nkx2.2 and Nkx6.1 (Figure 3C). The
anti-apoptotic gene Bcl-2 was also increased, however not
significantly. These results suggested that in addition to signifi-
cantly increasing DNA synthesis and b-cell proliferation, L-WRN+
treatment may exert positive effects on the maintenance of b-cell
Figure 3. Activation of Wnt and inhibition of RhoA/ROCK signaling significantly increase proliferation of adult human b-cells. Islets
(65) were cultured for 5 days in CMRL-1066 medium containing 10% FBS and 5 or 8 mM glucose or in 50% Wnt3a, R-spondin-3 and Noggin
conditioned medium (L-WRN) 6 5 or 8 mM glucose 6 Y-27632 and SB-431542 inhibitors as indicated. Samples were processed for
immunohistochemistry as described in Materials and Methods. (A) Quantitative measurements of the % of Ki-67+and insulin+ cells/total insulin+
cells. For each experimental treatment 4500–7500 b-cells were counted in three independent experiments. (B) Representative immunofluorescence
image of human islets treated for 5 days with L-WRN plus Y-27632 and SB-431542 inhibitors then dispersed into single cells and stained. Pink nucleus,
Ki-67+; green, insulin+; and blue, nuclei stained with DAPI. (C) 75 islets were cultured for 8 h in CMRL-1066 medium containing 10% FBS and 5 mM
glucose or in 50% Wnt3a, R-spondin-3 and Noggin conditioned medium (L-WRN) 6 Y-27632 and SB-431542 inhibitors as indicated. Samples were
processed for qRT-PCR and levels of mRNA for Insulin, Pdx1, Nkx2.2, Nkx6.1 and Bcl2 were determined as described in Materials and Methods.
Transcripts were normalized to b-actin at the corresponding time point. Data are the means6 SE of n = 3. *P,0.05, **P,0.01 and ***P,0.001 denote
significant differences between the treatment condition and the control.
doi:10.1371/journal.pone.0066131.g003
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Figure 4. Treatment of human islets with L-WRN+ regulates large numbers of proliferative genes. (A) mRNAs upregulated in response to
L-WRN+ by 1.5-fold vs treatment with 8 mM glucose alone, in islets sourced from two different donors. Relative mRNA levels in 5 mM glucose (5),
8 mM glucose (8), 8 mM glucose+LiCl (8+L) and L-WRN+-treated islet aliquots are shown; blue indicates lower abundance, red indicates higher
abundance. (B) as for (A), but showing those mRNAs downregulated by 1.5-fold in response to L-WRN+ treatment. (C) qRT-PCR validation of six
regulated and four nonregulated mRNAs (Mafa, Mnx1, Neurod1, Pax6); fold-changes of L-WRN+ treatment vs 8 mM glucose are shown. Individual
gene expression values were normalized to the geometric mean of B2m, Gapdh, Hmbs and Ywhaz [70]. White and black bars, fold-changes observed
with RNA-sequencing; red and blue bars, fold-changes observed with qRT-PCR. (D, upper) Classification of upregulated genes into Gene Ontology
categories; the most significantly over-represented categories are shown. (D, lower) Classification of upregulated genes into MetaCore custom-
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phenotype and survival of human islets through the up-regulation
of key transcription factors.
To further explore pro-b-cell and pro-survival effects of L-
WRN+, we subjected two independent preparations of human
islets to whole-transcriptome, quantitative gene expression assays
via RNA-sequencing. In response to 48 h L-WRN+ treatment,
transcripts for 974 genes were enriched by at least 1.5-fold, while
transcripts for 991 genes were diminished by at least 1.5-fold (from
a total of 15,599 reliably detected) in comparison to islet aliquots
from the same donors cultured at the same glucose concentration
in standard medium (Figure 4A and 4B, Table S1). Elevation of
glucose from 5 to 8 mM, or co-treatment with LiCl at 8 mM
glucose, led to minimal alterations in the mRNAs strongly
regulated by L-WRN+ (Figure 4A and 4B); only 175 transcripts
of the total 1,965 regulated by L-WRN+ were altered by the
change of glucose from 5 to 8 mM (Table S1). Genes encoding
enriched transcripts were significantly over-represented in Gene
Ontology processes of cell cycle regulation and cytoskeletal
rearrangements related to mitosis; upregulation of such processes
was expected from our data on L-WRN+-stimulated proliferation
measured by Ki-67 staining (Figure 4D, Table S2). Genes
encoding transcripts that were diminished in L-WRN+ treated
islets were represented by categories including ion transport, cell
adhesion and development (Figure 4E, Table S3). We investigated
a large number of islet or b-cell-specific genes and observed
regulation in a direction suggestive of increased differentiation for
several of these in response to L-WRN+ (Table S4); however, a
number of genes were altered in a manner resembling changes
observed in disease, e.g. downregulation of Slc2a2/Glut2, Glp1r,
and Slc30a8 (ZnT8), as also shown in Figure 4C. These data
demonstrate that L-WRN+ stimulates transcriptional programs in
human islets that activate proliferation without causing substantial
de-differentiation of b-cells, although the transcriptional profile of
these b-cells cannot be said to be entirely normal.
We hypothesized that the beneficial effects of L-WRN+ could
be due, at least in part, to increased expression of components of
the Wnt signaling pathway in response to chronic exposure to
secreted Wnt3a and R-spondin-3. Indeed, two of the signaling
networks populated by enriched transcripts included the Wnt
pathway (Figure 5A) (i.e. Sfrp1, Sfrp2, the Dishevelled homolog
Dvl1, the Dvl-binding protein Nkd1 and the Tcf-family transcrip-
tion factor, Tcf7l2) together with a Ki-67- and Sp1-centric
network) (Figure 5B). As expected, several members of TGF-b
related signaling networks were diminished in representation in
response to L-WRN+, including Tgf-b itself, p21/Cdkn1a and
collagens (Figure 5C). The enrichment of Axin2 and c-Myc, two
downstream targets of Wnt, was validated in separate preparations
of human islets using qRT-PCR, and was demonstrably higher in
response to L-WRN+ than with LiCl alone or L-WRN (without
RhoA/ROCK inhibitors) (Figures 5D & 5E).
L-WRN and L-WRN+ promote crosstalk between Wnt and
PKA signaling
Our previous studies showed that chronic activation of mTOR/
S6K1 leads to inhibition of the insulin signaling pathway and
reduced Akt phosphorylation. These findings also showed that
direct inhibition of GSK-3 by LiCl enhanced proliferation, but did
not restore the insulin-signaling pathway [18]. CREB is an
essential transcription factor for Irs gene expression [55]. In the
current study, we examined the effects of L-WRN or L-WRN+ on
expression of the CREB target genes Nr4a2 and Irs2, and Akt
phosphorylation. Figure 6A indicates that treatment of human
islets for 8 h with L-WRN+ increased CREB activity as indicated
by an increase in Nr4a2 and Irs2 gene expression. Importantly,
Figure 6B shows that activation of Wnt signaling at the level of
GSK-3 inhibition by LiCl had no effect on enhancing Akt
phosphorylation (lanes 1 vs 2), whereas engaging Wnt signaling at
the receptor level with L-WRN or L-WRN+ resulted in significant
increases in Akt phosphorylation at Ser473 (Figure 6B lanes 1 vs. 3
and 4). These results suggest that engaging Wnt signaling with L-
WRN or L-WRN+ treatment reduces insulin signaling pathway
resistance, whereas direct inhibition of GSK-3 with LiCl does not.
Since PKA signaling is known to be important for b-cell gene
expression and proliferation, we determined whether PKA was
involved in L-WRN+ or LiCl-mediated DNA synthesis. H-89, an
inhibitor of PKA, significantly blocked increases in DNA synthesis
in response to LiCl (Figure 6C) and L-WRN+ (Figure 6D).
Overall, these results suggest that L-WRN+ promotes crosstalk
between PKA, Wnt/b-catenin and Akt signaling in human islets to
enhance proliferative processes.
Activation of cAMP/PKA/CREB signaling pathway
engages both canonical Wnt/b-catenin and IRS2/Akt
pathways in human islets
Previous studies in NIH 3T3 kidney and HEK293 fibroblast rat
cell lines have shown that increasing intracellular levels of cAMP
induces PKA-dependent phosphorylation and inactivation of
GSK-3 [35]. Here, we show that treatment of human islets with
the cell-permeable activator of adenylyl cyclase, forskolin, signif-
icantly increased CREB phosphorylation (Figure 7A) and signif-
icantly induced phosphorylation of GSK-3a and GSK-3b at Ser21
and Ser9, respectively (Figure 7B). However, pretreatment of
human islets with the PKA inhibitor, H-89, significantly blocked
CREB phosphorylation (Figure 7A) and markedly reduced GSK-3
phosphorylation induced by forskolin (Figure 7B). Since Akt can
also induce phosphorylation and inactivation of GSK-3, we
pretreated human islets with the Akt inhibitor XII to exclude the
possibility that PKA induces GSK-3 phosphorylation through
activation of PI3K/Akt signaling. Human islets pretreated for 1 h
with the Akt inhibitor XII showed significant reduction of Akt
phosphorylation at Ser473 (Figure 7C) however, forskolin-induced
GSK-3 phosphorylation was not altered in these islets (Figure 7B).
These results suggest that activation of cAMP/PKA may engage
canonical Wnt signaling through PKA inhibition of GSK-3.
However, these results do not exclude that GSK-3 phosphoryla-
tion may also be induced through Akt.
To determine whether activation of cAMP/PKA/CREB
signaling also engages Irs2/Akt signaling under our treatment
conditions, we measured the mRNA levels of the CREB target
gene, Nr4a2, as well as Irs2 in response to forskolin treatment.
Isolated human islets were treated with forskolin in the presence of
5 or 20 mM glucose for 30 min, 4 and 8 h. Forskolin treatment at
either 5 or 20 mM glucose increased Irs2 mRNA levels 1.3-fold
after 30 min and remained 2.4-fold higher than controls after 4
and 8 h (Figure 7D). Treatment with 20 mM glucose alone did not
increase the Irs2 mRNA level. Consistent with the role of forskolin
in increasing cAMP levels, the expression of Nr4a2 was also
increased after 30 min (Figure 7D). These data indicate that
activation of the cAMP/PKA signaling pathway may activate
defined categories. (E, upper and lower) as for (D), but showing downregulated genes. Further details of Gene Ontology and MetaCore assignments
are provided in Tables S2 and S3.
doi:10.1371/journal.pone.0066131.g004
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Figure 5. Inclusion of L-WRN+-regulated mRNAs in Wnt-related, proliferative and TGF-b signaling networks. (A) Partial network of Wnt
signaling; red squares designate mRNAs upregulated by at least 1.5-fold in response to L-WRN+. (B) Proliferative signaling network focused on Ki-67
and Sp1. (C) Partial network of TGF-b signaling. Up and downregulated mRNAs in panels A–C were defined using RNA-sequencing; red squares
designate mRNAs upregulated by at least 1.5-fold in respone to L-WRN+; blue squares designate downregulated mRNAs. Green connecting lines
indicate activation, red connecting lines indicate inhibition, and gray lines indicate mixed or uncertain effects, according to previously published
studies contained in the curated MetaCore database. (D & E) Wnt pathway targets Axin2 and c-Myc compared amongst treated islets using qRT-PCR.
Islets (75) were cultured for indicated times in CMRL-1066 medium containing 10% FBS and 5 mM glucose 6 5 mM LiCl or in 50% Wnt3a, R-spondin-
3 and Noggin conditioned medium (L-WRN) 6 Y-27632 and SB-431542 inhibitors as indicated. Samples were processed for qRT-PCR and levels of
mRNA for Axin2 and c-Myc were determined as described in Materials and Methods. Transcripts were normalized to b-actin at the corresponding time
point. Data are the means 6 SE of n = 3 biological replicates. *P,0.05, **P,0.01 and ***P,0.001 denote significant differences between the
treatment condition and the control.
doi:10.1371/journal.pone.0066131.g005
Figure 6. L-WRN+ promotes crosstalk between Wnt and PKA/CREB and Akt signaling in human islets. (A) Islets (75) were incubated for
8 h in CMRL-1066 medium containing 10% FBS and 5 mM glucose or in 50% Wnt3a, R-spondin-3 and Noggin conditioned medium (L-WRN)+Y-27632
and SB-431542 inhibitors as indicated. The levels of mRNA for Nr4a2 and Irs2 were determined as described in Material and Method. The values
represent the –fold change due the indicated treatment over 5 mM glucose control treatment. (B) Islets (150) were treated for 24 h in CMRL-1066
medium containing 10% FBS and 5 mM glucose 6 5 mM LiCl or in 50% Wnt3a, R-spondin-3 and Noggin conditioned medium (L-WRN) 6 Y-27632
and SB-431542 inhibitors. Samples were processed for Western blotting and quantitated by Image LabTM software. pAkt protein was normalized to
total Akt protein. Data are the means 6 SE of n = 3. *P,0.05 and **P,0.01 denote significant differences between the treatment condition and
respective control. (C) & (D) islets (100) were cultured for 4 days as indicated. 3H-thymidine was added 24 h before the end of the 4-day period. Data
are the means 6 SE of n= 3 with duplicate samples in each experiment. **P,0.01 and ***P,0.001 denote significant differences between the
bracketed condition.
doi:10.1371/journal.pone.0066131.g006
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CREB and promote the expression of Irs2, thus engaging the Irs2/
Akt signaling pathway.
Pretreatment of human islets with L-WRN+ to increase
proliferation does not diminish subsequent glucose-
stimulated insulin secretion or insulin content
In Figure 8A, islets were cultured for 5 days in 8 mM glucose
alone or in combination with L-WRN or L-WRN+. The media
was removed and islets rested for 2 h in cCMRL containing 5 mM
glucose. Islets were then assayed for glucose-stimulated insulin
secretion. Insulin secretion was significantly increased in response
to 16.5 mM glucose compared to 5 mM glucose, in control, L-
WRN or L-WRN+ treated islets. The maximum level of insulin
secretion was also determined in response to 16.5 mM glucose in
the presence of forskolin to increase cAMP concentrations. In
Figure 8B insulin content was assayed at Time 0 and after 5 days
treatment with 5 or 8 mM glucose, L-WRN or L-WRN+. There
was no significant difference in insulin content between Time 0
(the time the islets arrived from the IIDP center) or following the 5-
day treatment period.
In Figure 8C and 8D, this same protocol as described in
Figure 8A and 8B was performed, except islets were allowed to
recover in cCMRL 5 mM glucose for 24 h. Glucose-stimulated
insulin secretion in response to 16.5 mM glucose 6 forskolin was
Figure 7. Activation of cAMP/PKA/CREB engages canonical Wnt and IRS2/Akt signaling in human islets. (A) & (B) & (C) Human islets
(150) were treated for 3 h with CMRL-1066 medium containing 10% FBS, 5 or 20 mM glucose, 6 10 mM forskolin 65 mM LiCl as indicated. The PKA
inhibitor (H-89, 10 mM) and Akt inhibitor (Akt inhibitor XII, 10 mM) were added to the culture where indicated 1 h before stimulation. Cell lysates were
prepared and analyzed for CREB-, Akt- and GSK-3 phosphorylation using specific antibodies as described in Materials and Methods. In (B) open
columns represent pGSK-3a and black columns represent pGSK-3b. (D) Human islets (75) were incubated for 30 min, 4 and 8 h with 5 or 20 mM
glucose, 610 mM forskolin. The levels of mRNA for Nr4a2 and Irs2 were determined as described in Materials and Methods. The values represent the
fold change due to the indicated treatment over 5 mM glucose control treatment. Data are the means 6 SE of n= 3 experiments. *P,0.05 **P,0.01
and ***P,0.001 denote significant differences between treatment conditions and the respective control (5 mM glucose).
doi:10.1371/journal.pone.0066131.g007
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increased ,5–6 fold compared to 5 mM glucose and the insulin
content was maintained under all treatment conditions. Collec-
tively, these findings indicate that L-WRN+ treatment significantly
increases b-cell proliferation, while preserving human b-cell
glucose-stimulated insulin secretion and content.
Discussion
In this study, we utilized a novel conditioned medium to
unmask the proliferative capacity of b-cells in intact human islets
while maintaining the b-cell phenotype. The conditioned medi-
um+ (L-WRN+) expresses elevated levels of Wnt3a, R-spondin-3,
and Noggin and contains the ROCK inhibitor (Y-27632) and SB-
431542 (that results in RhoA inhibition). As shown schematically
(Figure 9), activation of Wnt signaling at the receptor level with L-
WRN+ engages both canonical and non-canonical Wnt signaling
but also activates RhoA resulting in degradation of IRS1/2 and
inhibition of the insulin signaling pathway.
RhoA and its downstream effector, Rho-kinase (ROCK), are
involved in the development of insulin resistance, regulation of
insulin action and glucose homeostasis [56,57]. Activation of Rho/
ROCK signaling has been shown to increase serine phosphory-
lation of insulin receptor substrate-1/2 (IRS1/2) leading to its
proteasomal degradation and negatively regulates Akt signaling
Figure 8. L-WRN+ treatment does not impair insulin secretion. Islets (100) were cultured for 5 days in CMRL-1066 medium containing 10%
FBS and 8 mM glucose or in 50% Wnt3a, R-spondin-3 and Noggin conditioned medium (L-WRN)68 mM glucose6 Y-27632 and SB-431542 inhibitors
as indicated. (A) & (C) Following 5 days incubation, treatments were removed and islets were incubated for 2 h or 24 h, respectively, in cCMRL with
5 mM glucose. Insulin secretion was measured by a static incubation for 1 h in cCMRL containing 5, 16.5 mM glucose 6 forskolin. Quadruplicates of
10 islets were assayed. (B) & (D) Insulin content was measured from 20 islets in triplicate at the start of the incubation period (Time 0) and after 5 or 6
days of incubation, respectively, under the conditions shown. Insulin content in islets was extracted by the acid/ethanol method. Insulin secretion
and content were detected using Immulite 1000 system and their values were normalized to islet protein. Data are the means 6 SE of n= 3 with
duplicate samples in each experiment. *P,0.05 and **P,0.01 denote significant differences between the treatment condition and respective control.
doi:10.1371/journal.pone.0066131.g008
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[58,59]. In contrast, inhibition of Rho/ROCK signaling reduces
insulin resistance by increasing the tyrosine phosphorylation of
IRS1/2 and Akt phosphorylation [59,60].
In our approach, we inhibited ROCK signaling directly with Y-
27632 [61,62]. In addition, Rho/ROCK signaling was targeted
upstream with SB-431542, a small competitive inhibitor of TGF-
bRI superfamily activin-like kinase (ALK) receptors that inhibits
TGF-b mediated activation of RhoA, and blocks RhoA-down-
stream signaling (Figure 9) [63]. Including these inhibitors in our
medium (L-WRN+) resulted in the phosphorylation of Akt in
human islets, indicating a reduction of insulin signaling pathway
resistance (Figure 6B). Chronic hypoxia has been shown to
increase signaling through multiple pathways including the RhoA/
ROCK pathway [64,65]. It is probable that the hypoxic
conditions associated with the isolation of human islets from
cadaveric donors and their shipment upregulates RhoA/ROCK
signaling [19,66].
Further support for the importance of using the combination of
L-WRN and RhoA/ROCK inhibitors (L-WRN+), is that treat-
ment of human islets with RhoA/ROCK inhibitors alone only
produced a modest increase in DNA synthesis comparable to that
obtained with LiCl alone, demonstrating the necessity of the
Wnt3a, R-spondin-3 and Noggin components (Figure 2A). In
addition, RhoA/ROCK inhibitors did not increase DNA synthesis
in combination with LiCl. It is possible that over-inhibition of
GSK-3 with LiCl could decrease the phosphorylation of CREB at
Ser129 and trigger the dephosphorylation of Ser133. In addition,
over-inhibition of GSK-3 may inhibit protein kinases that
phosphorylate CREB at Ser133 such as PKA, PKC and p38
[67]. Thus, engaging Wnt signaling at the receptor level in
combination with RhoA/ROCK inhibition is required to achieve
significant levels of human b-cell proliferation.
An important consideration in the use of L-WRN+ is the
maintenance of b-cell phenotype and function. L-WRN+ treat-
ment of human islets results in accumulation of nuclear b-catenin
and stimulates the expression of multiple b-catenin target genes
(Figure 1C, 5D and 5E) and b-cell specific gene expression
(Figure 2C). In addition, L-WRN+ treatment increases gene
expression of CREB target genes, Nr4a2 and Irs2, and reduces islet
insulin signaling pathway resistance indicated by increased
phosphorylation of Akt (Figure 6A and 6B). Although L-WRN+
treatment strikingly increases proliferation, it does not significantly
reduce insulin content or alter glucose stimulated insulin secretion.
Importantly, the preservation of insulin secretion and content is
observed following the removal of L-WRN+, and may well make
this strategy applicable to ex vivo b-cell expansion prior to
transplantation.
This study also provides insights into how L-WRN+ promotes
the necessary crosstalk between multiple signaling pathways that
regulate proliferation and maintenance of the phenotype of human
b-cells, including activation of the insulin/Akt, mTOR, Wnt/b-
catenin, PKA/CREB signaling pathways, and inhibition of the
RhoA/ROCK pathway. During isolation and shipping, human
islets are exposed to stress-related hypoxia. This increases RhoA/
ROCK signaling and chronic mTOR activation resulting in
insulin resistance. Thus, neither Wnt/b-catenin nor insulin/IGF1
signaling is engaged. Wnt signaling is engaged at the receptor level
with Wnt3a and R-spondin-3 that activates canonical and non-
canonical Wnt pathways. b-catenin is translocated to the nucleus
due to GSK-3 inhibition and in combination with Rac1 signaling
[68,69], increases b-catenin-dependent gene transcription. As we
have previously described, appropriate mTOR activity is required
for b-catenin nuclear translocation [6]. Non-canonical Wnt
pathway activation increases RhoA/ROCK signaling that results
in degradation of IRS1/2 and negatively affects Akt phosphory-
lation. Inhibiting RhoA/ROCK signaling with SB-431542 and Y-
27632 reduces the insulin signaling pathway resistance. Our data
also suggest that Wnt-mediated DNA synthesis in human islets is
PKA dependent, based on H-89 inhibition (Figure 6C and 6D).
Furthermore, CREB signaling increases Nr4a2 and Irs2 gene
expression and increases Akt phosphorylation (Figure 6A and 6B).
In summary, we have used a novel conditioned medium
expressing Wnt3a, R-spondin-3 and Noggin to engage Wnt
signaling at the receptor level in combination with RhoA/ROCK
inhibitors, SB-431542 and Y-27632, to significantly enhance adult
human b-cell proliferation and maintain b-cell specific gene
expression, insulin secretion and content in intact islets. An
advantage of using this conditioned medium is to achieve
Figure 9. Proposed regulation of Wnt and Rho/ROCK signaling pathways by L-WRN+ in human islets.
doi:10.1371/journal.pone.0066131.g009
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activation of both canonical and non-canonical Wnt pathways (in
a manner that is not possible with exogenous addition of
conventional Wnt ligands to culture media) to significantly
enhance b-catenin nuclear translocation and proliferative gene
expression activity. This study also sheds light on the importance
of inhibiting RhoA/ROCK signaling in combination with Wnt
signaling to reduce human b-cell insulin signaling pathway
resistance. Treatment of adult human islets with this conditioned
medium provided highly reproducible effects on proliferation and
b-cell specific gene expression independent of the donor’s
biometrics or origin from different isolation centers. The
significance of these findings is that adult human b-cells in vitro
exhibit substantial levels of proliferation when the proliferative
capacity of b-cells is unmasked with appropriate trophic factors,
while maintaining the intact islet architecture. Future in vitro
studies will be conducted to determine the specificity or otherwise
of L-WRN+ treatment on the proliferation of b-cells and other
islet cell types, in particular a-cells. This study provides new
insights into the pathways involved in human b-cell proliferation
and the maintenance of the b-cell phenotype and offers a viable
method for ex vivo b-cell expansion.
Supporting Information
Table S1 mRNAs regulated by at least 1.5-fold in either
direction, assessed by RNA-sequencing, in both of 2 separate islet
preparations. Two islet preparations (from different donors) were
subjected to RNA-sequencing; within each preparation, subsets of
islets were treated with 5 or 8 mM glucose, 8 mM glucose +5 mM
LiCl or 8 mM glucose together with L-WRN+. RNA preparation
and analysis are documented in the main Methods text. The Table
shows those mRNAs regulated similarly in both islet preparations
between 8 mM glucose/L-WRN+ and 8 mM glucose alone (fold
change of at least 50%, in the same direction); separate columns
denote those mRNAs for which changes of this magnitude were
observed between 8 mM glucose alone and 5 mM glucose. Read
count data (normalized for differences in the total reads obtained
for each sample) are given for 5 mM glucose, 8 mM glucose and
8 mM glucose/L-WRN+ conditions for each islet preparation.
(XLS)
Table S2 Gene Ontology and MetaCore process network
descriptions for genes upregulated by L-WRN+. Category names
are shown together with a p-value denoting the significance of
gene over-representation in that category (all p-values shown are
significant at a false discovery rate ,0.05). Numbers in green text
denote the number of genes from the L-WRN+ upregulated
dataset; numbers in red denote the total number of human genes
that are members of that category. The first tab of the Excel file
shows Gene Ontology categorization; the second tab displays
MetaCore (Thomson Reuters, http://thomsonreuters.com/
products_services/science/systems-biology/) process descriptions.
(XLS)
Table S3 Gene Ontology and MetaCore process network
descriptions for genes downregulated by L-WRN+. As for Table
S2, but for downregulated genes.
(XLS)
Table S4 Genes of particular functional importance to b-cells
and islets in response to L-WRN+ treatment. Two islet
preparations (from different donors) were subjected to RNA-
sequencing as described for Table S1. The Table shows mRNAs
regulated in both islet preparations between 8 mM glucose/L-
WRN+ and 8 mM glucose alone. Significantly changed expression
(50% change in both preparations, in the same direction) is
denoted in bold. Only those genes with directionally similar
changes in both islet preparations, or lack of regulation in both
islet preparations, are shown. Read count data (normalized for
differences in the total reads obtained for each sample) are given
for the 8 mM glucose condition. Gene lists are drawn from
references as follows: 1) Anderson et al., BMC Dev Biol (2009)
9:65; 2) Kutlu et al., BMC Med Genomics (2009) 2:3; 3) Taneera
et al., Cell Metab (2012) 16:122–134.
(XLS)
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